Synthetic Approaches to the New Drugs Approved During 2022

被引:11
作者
France, Scott P. [1 ]
Lindsey, Erick A. [2 ]
McInturff, Emma L. [3 ]
Berritt, Simon [3 ]
Carney, Daniel W. [2 ]
DeForest, Jacob C. [4 ]
Fink, Sarah J. [5 ]
Flick, Andrew C. [2 ]
Gibson, Tony S. [2 ]
Gray, Kaitlyn [3 ]
Johnson, Amber M. [3 ]
Leverett, Carolyn A. [3 ]
Liu, Yiyang [3 ]
Mahapatra, Subham [3 ]
Watson, Rebecca B. [4 ]
机构
[1] Merck & Co Inc, Proc Res & Dev, Rahway, NJ 07065 USA
[2] Takeda San Diego, San Diego, CA 92121 USA
[3] Pfizer Inc, Groton, CT 06340 USA
[4] Pfizer Inc, San Diego, CA 92130 USA
[5] Crosswalk Therapeut, Cambridge, MA 02139 USA
关键词
ORALLY BIOAVAILABLE INHIBITOR; CELL LUNG-CANCER; 1ST APPROVAL; DOUBLE-BLIND; PHASE-II; IN-VITRO; POTENT; IDENTIFICATION; SAFETY; PHARMACOKINETICS;
D O I
10.1021/acs.jmedchem.3c02374
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In 2022, 23 new small molecule chemical entities were approved as drugs by the United States FDA, European Union EMA, Japan PMDA, and China NMPA. This review describes the synthetic approach demonstrated on largest scale for each new drug based on patent or primary literature. The synthetic routes highlight practical methods to construct molecules, sometimes on the manufacturing scale, to access the new drugs. Ten additional drugs approved in 2021 and one approved in 2020 are included that were not covered in the previous year's review.
引用
收藏
页码:4376 / 4418
页数:43
相关论文
共 249 条
[1]   Process Design and Optimization in the Pharmaceutical Industry: A Suzuki-Miyaura Procedure for the Synthesis of Savolitinib [J].
Adlington, Neil K. ;
Agnew, Lauren R. ;
Campbell, Andrew D. ;
Cox, Robert J. ;
Dobson, Andrew ;
Barrat, Cristina Fernandez ;
Gall, Malcolm A. Y. ;
Hicks, William ;
Howell, Gareth P. ;
Jawor-Baczynska, Anna ;
Miller-Potucka, Lucie ;
Pilling, Michael ;
Shepherd, Katy ;
Tassone, Ross ;
Taylor, Brian A. ;
Williams, Aled .
JOURNAL OF ORGANIC CHEMISTRY, 2019, 84 (08) :4735-4747
[2]   Mitapivat versus Placebo for Pyruvate Kinase Deficiency [J].
Al-Samkari, Hanny ;
Galacteros, Frederic ;
Glenthoj, Andreas ;
Rothman, Jennifer A. ;
Andres, Oliver ;
Grace, Rachael F. ;
Morado-Arias, Marta ;
Layton, D. Mark ;
Onodera, Koichi ;
Verhovsek, Madeleine ;
Barcellini, Wilma ;
Chonat, Satheesh ;
Judge, Malia P. ;
Zagadailov, Erin ;
Xu, Rengyi ;
Hawkins, Peter ;
Beynon, Vanessa ;
Gheuens, Sarah ;
van Beers, Eduard J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (15) :1432-1442
[3]  
Allan K. M., 2019, Patent No. [WO2019161280A1, 2019161280]
[4]  
Andrews I. P., 2019, patent, Patent No. [WO2019094934, 2019094934]
[5]  
[Anonymous], 2022, GLOBENEWSWIRE 0110
[6]  
[Anonymous], FDA Approves New Treatment for Pediatric Patients with Any Strain of Hepatitis C
[7]  
Ashwell S., 2016, patent, Patent No. [WO 2016044789, 2016044789]
[8]   Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors [J].
Bahleda, R. ;
Meric-Bernstam, F. ;
Goyal, L. ;
Tran, B. ;
He, Y. ;
Yamamiya, I ;
Benhadji, K. A. ;
Matos, I ;
Arkenau, H-T .
ANNALS OF ONCOLOGY, 2020, 31 (10) :1405-1412
[9]   Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity [J].
Barbachyn, MR ;
Hutchinson, DK ;
Brickner, SJ ;
Cynamon, MH ;
Kilburn, JO ;
Klemens, SP ;
Glickman, SE ;
Grega, KC ;
Hendges, SK ;
Toops, DS ;
Ford, CW ;
Zurenko, GE .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (03) :680-685
[10]   Development of a Green and Sustainable Manufacturing Process for Gefapixant Citrate (MK-7264) Part 3: Development of a One-Pot Formylation-Cyclization Sequence to the Diaminopyrimidine Core [J].
Basu, Kallol ;
Lehnherr, Dan ;
Martin, Gary E. ;
Desmond, Richard A. ;
Lam, Yu-hong ;
Peng, Feng ;
Chung, John Y. L. ;
Arvary, Rebecca A. ;
Zompa, Michael A. ;
Zhang, Si-Wei ;
Liu, Jinchu ;
Dance, Zachary E. X. ;
Larpent, Patrick ;
Cohen, Ryan D. ;
Guzman, Francisco J. ;
Rogus, Nicholas J. ;
Di Maso, Michael J. ;
Ren, Hong ;
Maloney, Kevin M. .
ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2020, 24 (11) :2462-2477